Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-452-9813
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.06 million
Profitability
Miscellaneous
Employees58
Next Earnings Date1/9/2020 (Estimated)
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) released its earnings results on Tuesday, March, 12th. The biotechnology company reported $0.18 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.43. The biotechnology company earned $19.69 million during the quarter. Advaxis had a negative return on equity of 67.08% and a negative net margin of 113.67%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
1 equities research analysts have issued 1 year price objectives for Advaxis' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Advaxis' share price to reach $4.00 in the next year. This suggests a possible upside of 1,108.1% from the stock's current price. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.
What are Wall Street analysts saying about Advaxis stock?
Here are some recent quotes from research analysts about Advaxis stock:
- 1. According to Zacks Investment Research, "Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P. " (10/14/2019)
- 2. HC Wainwright analysts commented, "We maintain our Neutral rating of ADXS and our 12-month price target of $4.30 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount)." (6/12/2019)
Has Advaxis been receiving favorable news coverage?
Media headlines about ADXS stock have trended somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advaxis earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Advaxis.
Are investors shorting Advaxis?
Advaxis saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 235,600 shares, a decline of 61.7% from the August 15th total of 615,600 shares. Based on an average daily volume of 1,880,000 shares, the short-interest ratio is currently 0.1 days. Currently, 1.0% of the company's shares are sold short. View Advaxis' Current Options Chain.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Kazia Therapeutics (KZIA), Aerpio Pharmaceuticals (ARPO), Evoke Pharma (EVOK), KemPharm (KMPH), AzurRx BioPharma (AZRX), AEterna Zentaris (AEZS), RegeneRx Biopharmaceuticals (RGRX), Soligenix (SNGX), Guardion Health Sciences (GHSI), Sophiris Bio (SPHS), ANCHIANO THERAP/S (ANCN), Amarillo Biosciences (AMAR), Acerus Pharmaceuticals (ASPCF), Cellectar Biosciences (CLRB) and Adial Pharmaceuticals (ADIL).
What other stocks do shareholders of Advaxis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Celgene (CELG), Anavex Life Sciences (AVXL), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), ContraVir Pharmaceuticals (CTRV) and Novavax (NVAX).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
- Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
- Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $0.33.
How big of a company is Advaxis?
Advaxis has a market capitalization of $5.70 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
